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Background and aim
Neuroblastoma (NB) is a tumour of the sympathetic nervous system, which arises from
the undiﬀerentiated precursor cells of the neural crest. This tumour aﬄicts children at an
early age and is characterised by its clinical heterogeneity which varies from spontaneous
regression to an aggressive phenotype and death. At least 40% of all children with NB are
confronted with an advanced stage of this disease [1]. The survival rates of a child with
high risk NB is estimated at 50%, despite the intensive and multimodal treatments [2].
The chromosomal characterisation of NB with arrayCGH has resulted in signiﬁcant con-
tributions in constructing a classiﬁcation model. This model consists of three genomic
subtypes [3]: low risk subtype 1 and high risk subtypes 2A and 2B. The analysis gave a
detailed insight into the recurring chromosomal abnormalities, as shown in Figure 1.
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Figure 1: Overview of the chromosomal abnormalities
for neuroblastoma subtypes 1, 2A and 2B.
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Figure 2: Survival plot of 176 neuroblastoma
patients.
The MYCN oncogene is highly ampliﬁed in NB subtype 2B tumors, in combination with a
high MYCN overexpression. The identiﬁcation of MYCN as driver gene for NB subtype 2B
tumors led to the identiﬁcation of some of the most abberated interactions [4]. Currently,
there are no known drivers for NB subtype 2A.
Aim
To develop a method based on diﬀerential networks (DN) designed for unravelling the
biological processes which lead to tumour growth in speciﬁc NB subtypes.
Diﬀerential networks aim to compare groups of patients – or more generally, organisms –
by construction interaction networks for each of the groups. A subnetwork which is very
characteristic and speciﬁc to one network in comparison to the other networks, might be
causal for the formation of tumours of that subtype. Such condition-speciﬁc subnetworks
might contain interesting targets for the development of more personalised drug treatments.
An example of a simple DN method is shown in Figure 3.
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Figure 3: An example of a diﬀerential network method.
Method
An outline of the methodology is shown in Figure 4. We used expression data from the
Neuroblastoma Research Consortium (NRC, a collaboration between several European NB
research groups) in order to infer two regulatory networks, one for NB 2A patients and one
for NB 2B patients. We inferred the networks using a variant of the GENIE3 [5] algorithm.
By grouping together strongly connected genes using MCL [6], we created a higher-order
structure in the graph, which we call a module, each representing a biological mechanism.
We gave each module in each of the networks a diﬀerentiality score. A score of 0 means
this module is not diﬀerential at all; that there is a module in the other network which is
exactly the same. A score of 1 means this module is very diﬀerential; there is no module
in the other network which is anything like the current module.
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Figure 4: The concept of diﬀerential module analysis for NB subtypes 2A and 2B.
Results
For both networks, we selected the top 3 most diﬀerential modules, and the top 3 least
diﬀerential modules. We performed an Gene Ontology enrichment analysis on each of the
modules, listed for each module the top 4 GO enrichments, and found that most modules
were enriched for biological processes related to oncogenesis, neural development or the
process of growth. This is not unexpected, as the samples were taken from neural tissue
of children with high risk NB.
There were two speciﬁc enrichments of interest. Firstly, the Wnt/β-catenin program has
previously been reported to be deregulated in high-risk NB without MYCN ampliﬁca-
tion [7], which matches the NB subtype 2A module in which this enrichment was found.
Secondly, Trk receptors were also previously reported as a prognostic marker for NB. A
high expression of the TrkA neutrophin receptor is associated with a good prognosis, while
a high expression of the TrkB neutrophin receptor usually occurs in high risk NB [8].
NB 2A speciﬁc (highly diﬀerential) module 1
• reg. of morphogenesis of a branching structure (p=2.8e-5)
• reg. of organ morphogenesis (p=6.4e-4)
• bone mineralization (p=1.9e-3)
• positive reg. of canonical Wnt signaling pathway (p=4.8e-3)
NB 2A speciﬁc (highly diﬀerential) module 2
• metal ion transport (p=1.8e-3)
• cation transport (p=6.1e-3)
• in utero embryonic development (p=7.5e-3)
• negative reg. of intestinal cholesterol absorption (p=8.3e-3)
NB 2A speciﬁc (highly diﬀerential) module 3
• protein activation cascade (p=4.8e-10)
• wound healing (p=1.4e-5)
• coagulation (p=1.7e-5)
• blood coagulation (p=1.7e-5)
NB 2B speciﬁc (highly diﬀerential) module 1
• cilium morphogenesis (p=5.2e-4)
• mannose biosynthetic process (p=9.5e-3)
• rRNA 5’-end processing (p=9.5e-3)
• septin cytoskeleton organization (p=9.5e-3)
NB 2B speciﬁc (highly diﬀerential) module 2
• sperm motility (p=1.9e-3)
• hexose biosynthetic process (p=3.4e-3)
• monosaccharide biosynthetic process (p=4.2e-3)
• hexitol catabolic process (p=5.5e-3)
NB 2B speciﬁc (highly diﬀerential) module 3
• ﬁbroblast growth factor receptor signaling pathway (p=1.4e-2)
• transcription initiation from RNA polymerase III promoter (p=1.5e-2)
• cellular response to ﬁbroblast growth factor stimulus (p=1.8e-2)
• response to ﬁbroblast growth factor (p=1.8e-2)
Common (highly similar) module 1
• pos. reg. of transcr. from RNA polymerase II promoter (p=8.1e-10)
• response to endogenous stimulus (p=7.8e-9)
• reg. of apoptotic process (p=8.9e-9)
• reg. of programmed cell death (p=1.0e-8)
Common (highly similar) module 2
• lung growth (p=9.1e-4)
• reg. of neurotrophin TRK receptor signaling pathway (p=1.3e-3)
• neg. reg. of peptidyl-threonine phosphorylation (p=2.2e-3)
• neg. reg. of ﬁbroblast growth factor receptor sign. pathway (p=2.7e-3)
Common (highly similar) module 3
• reg. of immune system process (p=9.1e-47)
• immune system process (p=1.1e-40)
• leukocyte activation (p=4.5e-36)
• lymphocyte activation (p=4.5e-36)
Common (highly similar) module 4
• response to cAMP (p=2.1e-6)
• response to corticosterone (p=3.4e-6)
• response to organophosphorus (p=6.4e-6)
• muscle organ development (p=1.4e-4)
Common (highly similar) module 5
• single-organism transport (p=2.3e-3)
• reg. of neurotransmitter secretion (p=9.8e-3)
• trochlear nerve formation (p=1.6e-2)
• trochlear nerve morphogenesis (p=1.6e-2)
Common (highly similar) module 6
• granzyme-mediated apoptotic signaling pathway (p=1.3e-2)
• reg. of sequestering of zinc ion (p=1.3e-2)
• synapse maturation (p=1.6e-2)
• post-embryonic organ morphogenesis (p=1.9e-2)
Conclusion
We performed a diﬀerential network analysis on NB expression data. Modules of interest
were analysed for Gene Ontology enrichment, after which NB experts immediately recog-
nised biological processes related to oncogenesis. This analysis serves as a prototype for
further diﬀerential network analyses for neuroblastoma research. Further research in the de-
velopment of diﬀerential networks is needed, however. Currently, this approach was solely
based on expression data, but more of the available data types need to be integrated into
the network to get a better understanding of the underlying processes. Furthermore, each
step in this analysis needs to be evaluated for robustness and performance, by adding slight
perturbations to the dataset and observing the eﬀects of the perturbations downstream.
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